Minimal Residual Disease Negativity Predicts Time to Next Treatment in Multiple Myeloma

WEDNESDAY, March 22, 2023 -- For patients with multiple myeloma (MM), minimal residual disease (MRD) negativity determined using next-generation sequencing (NGS) is predictive of longer time to next treatment (TTNT), according to a study published...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news